Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Chi-Joan How, Gabriela Hobbs, Aaron Gerds, Andriy Derkach, Emily Burton, Aurora Duran, Katherine Kan, Michael Mauro, Brian Chernak, Tamanna Haque, Raajit Rampal

Blood (2025) 146 (Supplement 1): 5606.

https://doi.org/10.1182/blood-2025-5606

Published: 2025

Journal Articles

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Jan Philipp Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Giuliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Ross Levine, Prithviraj Bose, Raajit Rampal

Blood (2025) 146 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2025-3814

Published: 2025

Journal Articles

TP53 mutated clonal hematopoiesis patterns over serial follow up: A single center clinic experience

Tamanna Haque, Nicola Kim, Gabrielle Arauz, Dipti Gupta, Andriy Derkach, Brittany Reid, Farzeen Aslam, Angela Brannon, Kelly Bolton, Roni Tamari, Simon Mantha, Ross Levine

Blood (2025) 146 (Supplement 1): 6706.

https://doi.org/10.1182/blood-2025-6706

Published: 2025

Journal Articles

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

Kuo-Kai Chin, Brian Ball, Yasmin Abaza, Jessica Altman, Rahul Thakur, Moiez Ali, Andriy Derkach, Mark Geyer, Aaron Goldberg, Tamanna Haque, Meghan Thompson, Jae Park, Martin Tallman, Sheng Cai, Eunice Wang, Ibrahim Aldoss, Eytan Stein

Blood (2025) 146 (Supplement 1): 39.

https://doi.org/10.1182/blood-2025-39

Published: 2025

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Blood (2024) 144 (Supplement 1): 655.

https://doi.org/10.1182/blood-2024-200312

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Jae H. Park, Lindsey Roeker, Martin S. Tallman, Maximilian Stahl, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 5962.

https://doi.org/10.1182/blood-2024-211733

Published: 2024

Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz

Blood (2024) 144 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2024-205697

Published: 2024

Journal Articles

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Ellin Berman, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Raajit K. Rampal, Jae H. Park, Lindsey E. Roeker, Martin S. Tallman, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 1519.

https://doi.org/10.1182/blood-2023-182012

Published: 2023

Journal Articles

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Guillermo Garcia-Manero, Melissa Ooi, Zhentang Lao, Harinder Gill, Yasmin Abaza, Maximilian Stahl, Tamanna Haque, Amy E. DeZern, Peter L. Greenberg, Marc Pelletier, Arti Singh, Daniel Carreon, Valerie Beaulieu, Janghee Woo

Blood (2023) 142 (Supplement 1): 3250.

https://doi.org/10.1182/blood-2023-174642

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism

Tamanna Haque, Arletta Lozanski, Tzyy-Jye Doong, Ying Huang, Rui Li, Abigail Bartosic, Gerard Lozanski, John C. Byrd, Tzu-Fei Wang

Blood (2021) 138 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2021-151696

Published: 2021

Journal Articles

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 2606.

https://doi.org/10.1182/blood-2021-146987

Published: 2021

Journal Articles

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Kieran D Sahasrabudhe, Melanie T Rebechi, Ying Huang, Greg K. Behbehani, Bhavana Bhatnagar, James S. Blachly, Bradley W Blaser, Uma Borate, Ramiro Garzon, Tamanna Haque, Karilyn Larkin, Meixiao Long, Alice S. Mims, Ayman Saad, Sumithira Vasu, Alison R. Walker, Sarah A Wall

Blood (2021) 138 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2021-148676

Published: 2021

Journal Articles

PI3Kinase Alpha and Delta Promote Hematopoietic Stem Activation Under Stress

Shayda Hemmati, PhD, Taneisha Sinclair, Meng Tong, Boris Bartholdy, PhD, Rachel Okabe, MD, Kristina Ames, PhD, Leanne Ostrodka, MD, Tamanna Haque, MD, Imit Kaur, PhD, Anupriya Agarwal, PhD, Jean Zhao, PhD, Thomas Roberts, PhD, Kira Gritsman, MD PhD

Blood (2018) 132 (Supplement 1): 329.

https://doi.org/10.1182/blood-2018-99-114891

Published: 2018

Journal Articles

First Report of Reversible Macrocytic Anemia with Dysplastic Features Associated with Palbociclib Use in Patients with Metastatic Breast Cancer

Tamanna Haque, MD, Jesus Anampa, MD, Irina Murakhovskaya, MD, Yanhua Wang, MD PhD, Kimo Bachiashvili, MD, Cristian Papazoglu, MD PhD, Kith Pradhan, PhD, Ulrich G. Steidl, MDPhD, Amit Verma, MD

Blood (2017) 130 (Supplement 1): 2207.

https://doi.org/10.1182/blood.V130.Suppl_1.2207.2207

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

TP53 mutated clonal hematopoiesis patterns over serial follow up: A single center clinic experience

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

PI3Kinase Alpha and Delta Promote Hematopoietic Stem Activation Under Stress

First Report of Reversible Macrocytic Anemia with Dysplastic Features Associated with Palbociclib Use in Patients with Metastatic Breast Cancer

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only